Statement of Changes in Beneficial Ownership (Form 4)

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Torley Helen 2. Issuer Name and Ticker or Trading Symbol HALOZYME THERAPEUTICS, INC. [HALO] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) PRESIDENT AND CEO (Last) (First) (Middle) C/O HALOZYME THERAPEUTICS, INC., 12390 EL CAMINO REAL 3. Date of Earliest Transaction (Month/Day/Year) 07/08/2025 (Street) SAN DIEGO, CA 92130 4. If Amendment, Date Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 07/08/2025 M(1) 20,000 A $8.11 753,719 D Common Stock 07/08/2025 S(1) 3,598 D $54.483(2) 750,121 D Common Stock 07/08/2025 S(1) 16,402 D $55.738(3) 733,719 D Common Stock 07/09/2025 M(1) 20,000 A $8.11 753,719 D Common Stock 07/09/2025 S(1) 19,792 D $56.426(4) 733,927 D Common Stock 07/09/2025 S(1) 208 D $57.076(5) 733,719 D Common Stock 07/10/2025 M(1) 20,000 A $8.11 753,719 D Common Stock 07/10/2025 S(1) 4,254 D $56.742(6) 749,465 D Common Stock 07/10/2025 S(1) 15,746 D $57.617(7) 733,719 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Option to Purchase Common Stock

$8.11

07/08/2025

M(1)

20,000

(8)

02/03/2026

Common Stock

20,000

$8.11

296,569

D

Option to Purchase Common Stock

$8.11

07/09/2025

M(1)

20,000

(8)

02/03/2026

Common Stock

20,000

$8.11

276,569

D

Option to Purchase Common Stock

$8.11

07/10/2025

M(1)

20,000

(8)

02/03/2026

Common Stock

20,000

$8.11

256,569

D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Torley Helen C/O HALOZYME THERAPEUTICS, INC. 12390 EL CAMINO REAL SAN DIEGO, CA 92130	X		PRESIDENT AND CEO

Signatures

/s/ James R. Oehler, Attorney-in-Fact		07/10/2025
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026.
(2)	Represents a weighted average sales price per share. The shares were sold at prices ranging from $54.17 to $55.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
(3)	Represents a weighted average sales price per share. The shares were sold at prices ranging from $55.17 to $56.16. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
(4)	Represents a weighted average sales price per share. The shares were sold at prices ranging from $56.055 to $57.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
(5)	Represents a weighted average sales price per share. The shares were sold at prices ranging from $57.05 to $57.10. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
(6)	Represents a weighted average sales price per share. The shares were sold at prices ranging from $56.184 to $57.17. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
(7)	Represents a weighted average sales price per share. The shares were sold at prices ranging from $57.185 to $57.94. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
(8)	Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 3, 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.